Programme Status
Month 3 of 6 · Stage-gate 2026-09-30
Four workstreams establishing the factual baseline for European pricing, tender positioning, evidence packaging and market access - feeding directly into the Phase 1 → Phase 2 Go / No-Go review.
50%
complete
Workstream status
WS1 Pricing
● AMBERPricing & Contract Intelligence
62%
1/3 deliverables
WS2 Competitors
● REDCompetitor Benchmarking
48%
1/3 deliverables
WS3 Evidence
● GREENEvidence Package Assessment
71%
2/3 deliverables
WS4 Market Access
● AMBERMarket Access Route Mapping
55%
1/3 deliverables
Programme phases
Phase 1
● In flightIntelligence Foundation
Months 1–6
- •Pricing & contract map
- •Competitor benchmarking
- •Evidence gap analysis
- •Market access routes
Phase 2
Strategic Development
Months 7–18
- •Global pricing framework
- •2029 launch strategy
- •KOL mapping
- •Outcomes study design
Phase 3
Operationalisation
Year 2+
- •Embedded monitoring
- •Launch execution support
- •Ongoing intelligence
- •Affiliate enablement
Live signals
● COMPETITORS
Portfolio gap: Novalac Allernova AR positioned as category-of-one EHF + anti-reflux thickener. No equivalent SKU in Aptamil Pepti or Cow & Gate Pepti range.
1 hr ago
● PRICING
Contract C-UK-208 flagged: net price 18% below corridor.
2 hr ago
● COMPETITORS
Novalac Allernova AR won DE tender T-DE-2026-04 (€1.4M).
5 hr ago
● EVIDENCE
ACFS adequacy dossier draft accepted for internal review.
yesterday
● ACCESS
G-BA scoping call confirmed for 2026-07-09.
yesterday
● COMPETITORS
Prescriber traction for Novalac Allernova AR +4pp month-on-month.
2 days
● PRICING
IT regional tender re-bid required (Lombardia).
3 days
Top risks
R1● RED
2029 combination anchor price erosion
Owner: Marie Sanderson
R2● RED
Portfolio gap: no combined EHF + AR SKU vs Novalac Allernova AR
Owner: WS2 / Med Affairs
R3● AMBER
Evidence gap vs G-BA dossier reqs
Owner: HEOR
R4● AMBER
Affiliate data normalisation slippage
Owner: Programme Ops
R5● GREEN
ACFS submission timing (UK)
Owner: Regulatory